Mobile

Study to assess the safety, tolerability and efficacy of AMG 145 in patients with heterozygous familial hypercholesterolemia

Update Il y a 4 ans
Reference: EUCTR2012-001365-32

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 every-2-weeks (Q2W) and monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with heterozygous familial hypercholesterolemia.

Inclusion criteria

  • Heterozygous Familial Hypercholesterolemia

Links